Intratumoral microbiome in clear cell renal cell carcinoma – a new factor in the tumor microenvironment
Authors:
Peter Polaček 1; Vojtěch Fiala 1; David Feldmar 2; Martin Matějů 3; Otakar Čapoun 1; Viktor Soukup 1
Authors‘ workplace:
Urologická klinika 1. LF UK a VFN v Praze
1; Onkologická klinika 2. LF UK a FN Motol a Homolka, Praha
2; Onkologická klinika 1. LF UK a VFN v Praze
3
Published in:
Ces Urol 2026; 30(3): 126-131
Category:
Review article
doi:
https://doi.org/10.48095/cccu2026018
Overview
Clear cell renal cell carcinoma (ccRCC), is the most common histological subtype of renal cell carcinoma and represents a significant oncological burden with particularly high incidence in European countries. In recent years, research has increasingly focused on the tumor microenvironment, which also includes the intratumoral microbiome – microorganisms present directly within tumor tissue. The aim of this review is to summarize current knowledge regarding the composition of the intratumoral microbiome in ccRCC, its relationship with the tumor immune microenvironment, and its potential prognostic significance. Available studies confirm the presence of bacterial DNA within ccRCC tumor tissue and demonstrate differences in microbial composition compared with adjacent non-tumorous tissue, including reduced alpha diversity. Specific microbial genera associated with overall survival and with patterns of immune cell infiltration have been identified. Some microorganisms appear to be linked to antitumor adaptive immune responses, whereas others are associated with an immunosuppressive tumor microenvironment and unfavorable prognosis. Current evidence also suggests a possible relationship between the microbiome and response to systemic therapy. Although existing evidence is largely observational and subject to methodological limitations, the intratumoral microbiome represents a promising field of research. Future studies should focus on methodological standardization and prospective validation of the clinical relevance of microbial signatures in patients with clear cell renal cell carcinoma.
Keywords:
immunotherapy – Immunity – Prognosis – clear cell renal cell carcinoma – tumor microenvironment – intratumoral microbiome – alpha diversity – 16S rRNA sequencing
Sources
1. Bray F, Laversanne M, Sung H et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74(3): 229–263. doi: 10.3322/caac.21834.
2. Ústav zdravotnických informací a statistiky ČR (ÚZIS). Novotvary 2019–2021 ČR. Praha: ÚZIS ČR 2023. [online]. Dostupné z: https://www.uzis.cz/res/f/008447/novotvary2019-2021.pdf.
3. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003; 16(1): 1–17. doi: 10.1128/CMR.16.1.1-17.2003.
4. Collatuzzo G, Pelucchi C, Negri E et al. Exploring the interactions between Helicobacter pylori (Hp) infection and other risk factors of gastric cancer: a pooled analysis in the Stomach cancer Pooling (StoP) Project. Int J Cancer 2021; 149(6): 1228–1238. doi: 10.1002/ijc.33678.
5. Wang J, Li X, Wu X et al Uncovering the microbiota in renal cell carcinoma tissue using 16S rRNA gene sequencing. J Cancer Res Clin Oncol 2021; 147(2): 481–491. doi: 10.1007/s00432-020-03462-w.
6. Nejman D, Livyatan I, Fuks G et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 2020; 368(6494): 973–980. doi: 10.1126/science.aay9189.
7. Xu H, Leng J, Liu F et al. Tumor microbiota of renal cell carcinoma affects clinical prognosis by influencing the tumor immune microenvironment. Heliyon 2024; 10(19): e38310. doi: 10.1016/j.heliyon.2024.e38310.
8. Gao S, Li S, Ma Z et al. Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer. Infect Agent Cancer 2016; 11 : 3. doi: 10.1186/s13027-016-0049-x.
9. Nosho K, Sukawa Y, Adachi Y et al. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol 2016; 22(2): 557–566. doi: 10.3748/wjg.v22.i2.557.
10. Riquelme E, Zhang Y, Zhang L et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 2019; 178(4): 795–806.e12. doi: 10.1016/j.cell.2019.07.008.
11. Tucker MD, Rini BI. Predicting response to immunotherapy in metastatic renal cell carcinoma. Cancers (Basel) 2020; 12(9): 2662. doi: 10.3390/cancers12092662.
12. Derosa L, Routy B, Fidelle M et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur Urol 2020; 78(2): 195–206. doi: 10.1016/j.eururo.2020.04.044.
13. Zhang J, Lou K, Chi J et al. Research progress on intratumoral microorganisms in renal cancer. World J Urol 2025; 43(1): 72. doi: 10.1007/s00345-024-05403-5.
14. Pushalkar S, Hundeyin M, Daley D et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov 2018; 8(4): 403–416. doi: 10.1158/2159-8290.CD-17-1134.
15. Foresto-Neto O, Ghirotto B, Câmara NO. Renal sensing of bacterial metabolites in the gut-kidney axis. Kidney360 2021; 2(9): 1501–1509. doi: 10.34067/KID.0000292021.
16. Chowdhury S, Matrana MR, Tsang C et al. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. Hematol Oncol Clin North Am 2011; 25(4): 853–869. doi: 10.1016/j.hoc.2011.05.003.
17. LaCourse KD, Zepeda-Rivera M, Kempchinsky AG et al. The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota. Cell Rep 2022; 41(7): 111625. doi: 10.1016/j.celrep.2022.111625.
18. Yu T, Guo F, Yu Y et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 2017; 170(3): 548–563.e16. doi: 10.1016/j.cell.2017.07.008.
19. Kovaleva OV, Podlesnaya P, Sorokin M et al. Macrophage phenotype in combination with tumor microbiome composition predicts RCC patientsʼ survival: a pilot study. Biomedicines 2022; 10(7): 1516. doi: 10.3390/biomedicines10071516.
20. Riquelme E, Zhang Y, Zhang L et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 2019; 178(4): 795–806.e12. doi: 10.1016/j.cell.2019.07.008.
Labels
Paediatric urologist Nephrology UrologyArticle was published in
Czech Urology
2026 Issue 3
Most read in this issue
- Papillary renal neoplasm with reverse polarity
- Vzdělávání – rozdíl mezi evropským standardem a českou praxí
- Peyronie’s disease (induratio penis plastica) – contemporary perspective on diagnosis and management in Czech clinical practice
- Central European Urology Meeting in Krakow 2026